Arshita Neni, Lestari Rizka V, Hutajulu Susanna H, Ghozali Ahmad, Paramita Dewi K
Department of Histology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia. Email:
Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3147-3152. doi: 10.31557/APJCP.2018.19.11.3147.
Objective: This study aimed to identify micro-satellite instability (MSI) based on the expression of MMRp (MSH2 and MSH6) and to evaluate the association of MSI and with clinicopathological features in patients with colorectal cancer (CRC). Methods: MMRp expression in 80 tissue samples from patients with adenocarcinoma CRC were evaluated by using anti-MSH2 and -MSH6 antibodies. Loss of MSH2 and/or MSH6 expression was stated as MSI. The association between MSI status and clinicopathological features were analyzed by using binary logistic regression (p<0.05). Results: The frequency of MSI in patients with CRC varied, corresponding to 8.3% (6/72) MSH2 MSI, 36.1% (26/72) MSH6 MSI and 6.9% (5/72) MSH2-MSH6 MSI. Male patients (OR=1.98), with tumor located in colon (OR=1.47) and late stage tumor (OR=1.48) have a tendency of having MSH2 MSI. Male patients (OR=1.4), with tumor located in colon (OR=2.53) and poor tumor differentiation (OR=3.02) have a tendency to encounter MSH6 MSI. Male patients (OR=4.93) with late stage tumor (OR=1.69) have a tendency of having MSH2-MSH6 MSI. Conclusion: Patients more likely to have MSH2 MSI are males, and/or having tumor located in colon, and /or having late stage tumor. Patients more likely to have MSH6 MSI are males, and/or having tumor located in colon, and/or having tumor with poor differentiation. Patients who have greater tendency to have MSH2 and MSH6 MSI are males, and/or having late stage tumor.
本研究旨在基于错配修复蛋白(MMRp,即MSH2和MSH6)的表达来识别微卫星不稳定性(MSI),并评估MSI与结直肠癌(CRC)患者临床病理特征之间的关联。方法:使用抗MSH2和抗MSH6抗体评估80例腺癌性CRC患者组织样本中的MMRp表达。MSH2和/或MSH6表达缺失被认定为MSI。采用二元逻辑回归分析MSI状态与临床病理特征之间的关联(p<0.05)。结果:CRC患者中MSI的发生率各不相同,其中MSH2 MSI为8.3%(6/72),MSH6 MSI为36.1%(26/72),MSH2 - MSH6 MSI为6.9%(5/72)。男性患者(OR = 1.98)、肿瘤位于结肠的患者(OR = 1.47)以及晚期肿瘤患者(OR = 1.48)有发生MSH2 MSI的倾向。男性患者(OR = 1.4)、肿瘤位于结肠的患者(OR = 2.53)以及肿瘤分化差的患者(OR = 3.02)有发生MSH6 MSI的倾向。男性患者(OR = 4.93)以及晚期肿瘤患者(OR = 1.69)有发生MSH2 - MSH6 MSI的倾向。结论:更易发生MSH2 MSI的患者为男性,和/或肿瘤位于结肠,和/或处于晚期。更易发生MSH6 MSI的患者为男性,和/或肿瘤位于结肠,和/或肿瘤分化差。更易发生MSH2和MSH6 MSI的患者为男性,和/或处于晚期。